Thalidomide and closely related analogues are used clinically for their immunomodulatory and antiangiogenic properties mediated by the inhibition of the proinflammatory cytokine tumor necrosis factor α. Neuroinflammation and angiogenesis contribute to classical neuronal mechanisms underpinning the pathophysiology of l-dopa-induced dyskinesia, a motor complication associated with l-dopa therapy in Parkinson's disease. The efficacy of thalidomide and the more potent derivative 3,6'-dithiothalidomide on dyskinesia was tested in the 6-hydroxydopamine Parkinson's disease model.
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease
Mulas, GiovannaMethodology
;Fenu, SandroConceptualization
;Carboni, EzioConceptualization
;Spiga, SaturninoConceptualization
;Carta, Anna R
Ultimo
Project Administration
2019-01-01
Abstract
Thalidomide and closely related analogues are used clinically for their immunomodulatory and antiangiogenic properties mediated by the inhibition of the proinflammatory cytokine tumor necrosis factor α. Neuroinflammation and angiogenesis contribute to classical neuronal mechanisms underpinning the pathophysiology of l-dopa-induced dyskinesia, a motor complication associated with l-dopa therapy in Parkinson's disease. The efficacy of thalidomide and the more potent derivative 3,6'-dithiothalidomide on dyskinesia was tested in the 6-hydroxydopamine Parkinson's disease model.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Boi_et_al-2019-Movement_Disorders.pdf
Solo gestori archivio
Descrizione: articolo principale
Tipologia:
versione post-print (AAM)
Dimensione
6.1 MB
Formato
Adobe PDF
|
6.1 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
CartaAR_Immunomodulatory-Drugs.pdf
accesso aperto
Tipologia:
versione editoriale (VoR)
Dimensione
6.14 MB
Formato
Adobe PDF
|
6.14 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.